EP3423094A4 - Gfral receptor therapies - Google Patents
Gfral receptor therapies Download PDFInfo
- Publication number
- EP3423094A4 EP3423094A4 EP16891935.5A EP16891935A EP3423094A4 EP 3423094 A4 EP3423094 A4 EP 3423094A4 EP 16891935 A EP16891935 A EP 16891935A EP 3423094 A4 EP3423094 A4 EP 3423094A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- receptor therapies
- gfral receptor
- gfral
- therapies
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2016/074809 WO2017147742A1 (en) | 2016-02-29 | 2016-02-29 | Gfral receptor therapies |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3423094A1 EP3423094A1 (en) | 2019-01-09 |
EP3423094A4 true EP3423094A4 (en) | 2019-11-06 |
Family
ID=59742416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16891935.5A Withdrawn EP3423094A4 (en) | 2016-02-29 | 2016-02-29 | Gfral receptor therapies |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3423094A4 (en) |
JP (1) | JP2019510739A (en) |
CN (1) | CN108697795A (en) |
WO (1) | WO2017147742A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012138919A2 (en) | 2011-04-08 | 2012-10-11 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
AU2017228489A1 (en) * | 2016-03-04 | 2018-09-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
PE20190126A1 (en) | 2016-03-31 | 2019-01-17 | Ngm Biopharmaceuticals Inc | BINDING PROTEINS AND METHODS OF USING THEM |
MA46523A (en) * | 2016-10-12 | 2019-08-21 | Janssen Biotech Inc | PROCESSES FOR SCREENING MODULATORS OF A GDF15 TYPE BIOLOGICAL ACTIVITY |
TWI724392B (en) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | Growth differentiation factor 15 agonist compounds and methods of using the same |
MX2021004665A (en) | 2018-10-22 | 2021-08-24 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof. |
WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
EP4163300A1 (en) * | 2020-06-04 | 2023-04-12 | Daegu Gyeongbuk Institute Of Science and Technology | Gfral-antagonistic antibody and use thereof |
CN116390925A (en) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | AMPK activator |
EP4314071A1 (en) | 2021-03-31 | 2024-02-07 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
WO2023274276A1 (en) * | 2021-06-30 | 2023-01-05 | 上海津曼特生物科技有限公司 | Anti-gfral antibody and application thereof |
CN116444667B (en) * | 2023-06-13 | 2023-09-01 | 上海驯鹿生物技术有限公司 | GDF 15-targeted fully-humanized antibody and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003076569A2 (en) * | 2002-03-05 | 2003-09-18 | Genentech, Inc. | Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same |
EP2694092A2 (en) * | 2011-04-08 | 2014-02-12 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
WO2017121865A1 (en) * | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Mic-1 receptor and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100278843A1 (en) * | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
CN102321173B (en) * | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | Humanized macrophage inhibitory factor 1 monoclonal antibody and application thereof |
JO3462B1 (en) * | 2012-08-22 | 2020-07-05 | Regeneron Pharma | Human Antibodies to GFR?3 and methods of use thereof |
DK2934584T3 (en) * | 2012-12-21 | 2020-05-18 | Aveo Pharmaceuticals Inc | ANTI-GDF15 ANTIBODIES |
-
2016
- 2016-02-29 EP EP16891935.5A patent/EP3423094A4/en not_active Withdrawn
- 2016-02-29 WO PCT/CN2016/074809 patent/WO2017147742A1/en active Application Filing
- 2016-02-29 CN CN201680082844.2A patent/CN108697795A/en active Pending
- 2016-02-29 JP JP2018540415A patent/JP2019510739A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003076569A2 (en) * | 2002-03-05 | 2003-09-18 | Genentech, Inc. | Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same |
EP2694092A2 (en) * | 2011-04-08 | 2014-02-12 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
WO2017121865A1 (en) * | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Mic-1 receptor and uses thereof |
Non-Patent Citations (2)
Title |
---|
See also references of WO2017147742A1 * |
VICKY W. W. TSAI ET AL: "Anorexia/cachexia of chronic diseases: a role for the TGF-β family cytokine MIC-1/GDF15", JOURNAL OF CACHEXIA, SARCOPENIA AND MUSCLE, vol. 3, no. 4, 31 December 2012 (2012-12-31), pages 239 - 243, XP055105895, ISSN: 2190-5991, DOI: 10.1007/s13539-012-0082-6 * |
Also Published As
Publication number | Publication date |
---|---|
JP2019510739A (en) | 2019-04-18 |
EP3423094A1 (en) | 2019-01-09 |
WO2017147742A1 (en) | 2017-09-08 |
CN108697795A (en) | 2018-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3226856A4 (en) | Combination therapies | |
EP3423094A4 (en) | Gfral receptor therapies | |
EP3212231A4 (en) | Anti-tim-3 antibodies | |
EP3212229A4 (en) | Anti-tim-3 antibodies | |
EP3224261A4 (en) | Opioid receptor modulators | |
EP3459756A4 (en) | Counterfeit-preventing structure | |
EP3253208A4 (en) | Combination therapies | |
EP3177650A4 (en) | Anti-ceramide antibodies | |
EP3204042A4 (en) | Psma-related therapies | |
EP3358740A4 (en) | Vibrating structure | |
EP3224230A4 (en) | Estrogen receptor modulators | |
AU2016904682A0 (en) | Construction System Components | |
AU2016903803A0 (en) | Putt-N-Pal | |
AU2016903627A0 (en) | ShishiaPlus | |
AU2016903439A0 (en) | Thermobrush | |
AU2016903334A0 (en) | FittConnect | |
AU2016903303A0 (en) | Gyrostabilisers | |
AU2016903360A0 (en) | Eza-foot | |
AU2016903171A0 (en) | postpull | |
AU2016903133A0 (en) | Blocksock | |
AU2016903015A0 (en) | BootOver | |
AU2016902910A0 (en) | BoardCarry | |
AU2016902711A0 (en) | Reflect-A-Coat | |
AU2016902439A0 (en) | Polybat | |
AU2016902398A0 (en) | Scaffgrip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181001 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20191009 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/395 20060101AFI20191002BHEP Ipc: A61K 45/06 20060101ALI20191002BHEP Ipc: A61K 38/17 20060101ALI20191002BHEP Ipc: A61P 3/04 20060101ALI20191002BHEP Ipc: A61P 3/08 20060101ALI20191002BHEP Ipc: A61P 3/10 20060101ALI20191002BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200603 |